Literature DB >> 8426105

Identification of human cancers deficient in antigen processing.

N P Restifo1, F Esquivel, Y Kawakami, J W Yewdell, J J Mulé, S A Rosenberg, J R Bennink.   

Abstract

Intracellular antigens must be processed before presentation to CD8+ T cells by major histocompatibility complex (MHC) class I molecules. Using a recombinant vaccinia virus (Vac) to transiently express the Kd molecule, we studied the antigen processing efficiency of 26 different human tumor lines. Three cell lines, all human small cell lung carcinoma, consistently failed to process endogenously synthesized proteins for presentation to Kd-restricted, Vac-specific T cells. Pulse-chase experiments showed that MHC class I molecules were not transported by these cell lines from the endoplasmic reticulum to the cell surface. This finding suggested that peptides were not available for binding to nascent MHC molecules in the endoplasmic reticulum. Northern blot analysis of these cells revealed low to nondetectable levels of mRNAs for MHC-encoded proteasome components LMP-7 and LMP-2, as well as the putative peptide transporters TAP-1 and TAP-2. Treatment of cells with interferon gamma enhanced expression of these mRNAs and reversed the observed functional and biochemical deficits. Our findings suggest that downregulation of antigen processing may be one of the strategies used by tumors to escape immune surveillance. Potential therapeutic applications of these findings include enhancing antigen processing at the level of the transcription of MHC-encoded proteasome and transporter genes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426105      PMCID: PMC1950463          DOI: 10.1084/jem.177.2.265

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  51 in total

1.  Monoclonal antibodies localize events in the folding, assembly, and intracellular transport of the influenza virus hemagglutinin glycoprotein.

Authors:  J W Yewdell; A Yellen; T Bächi
Journal:  Cell       Date:  1988-03-25       Impact factor: 41.582

Review 2.  Antigen recognition by class I-restricted T lymphocytes.

Authors:  A Townsend; H Bodmer
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 3.  Unique tumor-specific antigens.

Authors:  H Schreiber; P L Ward; D A Rowley; H J Stauss
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  H-2 restriction of adoptive immunotherapy of advanced tumors.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

5.  Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses.

Authors:  G L Smith; J Z Levin; P Palese; B Moss
Journal:  Virology       Date:  1987-10       Impact factor: 3.616

6.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

7.  Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus.

Authors:  B E Coupar; M E Andrew; D B Boyle; R V Blanden
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

8.  Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma.

Authors:  D A Carlow; R S Kerbel; B E Elliott
Journal:  J Natl Cancer Inst       Date:  1989-05-10       Impact factor: 13.506

9.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection.

Authors:  J S Weber; G Jay; K Tanaka; S A Rosenberg
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

View more
  144 in total

1.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.

Authors:  W Asavaroengchai; Y Kotera; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

2.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

3.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 4.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 5.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

6.  Identification of E2F1 as an important transcription factor for the regulation of tapasin expression.

Authors:  Juergen Bukur; Felix Herrmann; Diana Handke; Christian Recktenwald; Barbara Seliger
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

Review 7.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

8.  Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.

Authors:  Nehad M Alajez; Jan Schmielau; Mark D Alter; Michael Cascio; Olivera J Finn
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 9.  Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.

Authors:  Julie R Brahmer; Drew M Pardoll
Journal:  Cancer Immunol Res       Date:  2013-07-22       Impact factor: 11.151

Review 10.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.